| Factor Xa inhibitors--new anticoagulants for secondary haemostasis. | |
| | |
MedLine Citation:
|
PMID: 19644596 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Oral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest developments of oral direct FXa inhibitors and focuses on those which have been approved for the prevention of venous thromboembolism (VTE) after total hip or knee replacement or are in advanced development and have passed phase II (proof of principle) testing. The most advanced drugs are apixaban, betrixaban, edoxaban, eribaxaban, rivaroxaban, LY517717, TAK-442, and YM150. Rivaroxaban (Xarelto??) is the first direct FXa inhibitor which has recently been approved for the prevention of VTE in adult patients after elective hip or knee replacement in several countries, including the European Union and Canada. Rivaroxaban has a flat dose-dependent anticoagulant response with a wide therapeutic window and low potential for drug-drug and drug-food interactions. Rivaroxaban can be given in fixed doses without coagulation monitoring. This review describes the pharmacodynamic and pharmacokinetic profiles and the results of clinical trials with FXa inhibitors in the prevention and treatment of thromboembolic disorders. |
| | |
Authors:
|
E Perzborn |
Related Documents
:
|
18603996 - Interaction between warfarin and tamoxifen: a case report. 3797806 - Lack of pharmacodynamic interaction between pentoxifylline and warfarin in the rat. 18685566 - Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and th... 3084176 - Investigation of drug interactions with pinaverium bromide. 15207796 - Neurosarcoidosis: a clinical dilemma. 6496396 - The pharmacological studies in central nervous system on the interaction of taiwanese v... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: H??mostaseologie Volume: 29 ISSN: 0720-9355 ISO Abbreviation: Hamostaseologie Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-07-31 Completed Date: 2010-01-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8204531 Medline TA: Hamostaseologie Country: Germany |
Other Details:
|
Languages: eng Pagination: 260-7 Citation Subset: IM |
Affiliation:
|
Cardiovascular Pharmacology, Pharma R&D Discovery Research, Bayer Schering Pharma AG, Aprather Weg 18a, 42096 Wuppertal, Germany. elisabeth.perzborn@bayerhealthcare.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Anticoagulants / administration & dosage, therapeutic use* Factor Xa / antagonists & inhibitors* Glycine / administration & dosage, analogs & derivatives, therapeutic use Hemostasis / drug effects* Humans Morpholines / therapeutic use Piperazines / administration & dosage, therapeutic use Pyrazoles / administration & dosage, therapeutic use Pyridones / administration & dosage, therapeutic use Pyrrolidines / administration & dosage, therapeutic use Thiophenes / therapeutic use Venous Thromboembolism / prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/LY517717; 0/Morpholines; 0/N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidiine-1,2-dicarboxamide; 0/Piperazines; 0/Pyrazoles; 0/Pyridones; 0/Pyrrolidines; 0/Thiophenes; 0/apixaban; 0/rivaroxaban; 56-40-6/Glycine; EC 3.4.21.6/Factor Xa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiac resynchronization therapy in congestive heart failure: The state of the art and future persp...
Next Document: The present state of aspirin and clopidogrel resistance.